 The primary objective was to investigate the efficacy and safety of 0.05 difluprednate ophthalmic emulsion in patients with endogenous anterior uveitis and to determine its clinical usefulness for treatment of this disease in the early phase of development, in comparison with Rinderon solution containing 0.1 betamethasone sodium phosphate that has widely been used for treatment of postoperative inflammation, uveitis, etc. as a steroid ophthalmic solution. 